Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 2, 2008, Pages 140-156

  Connor, Daniel F ^a   McLaughlin, Thomas J ^b   Jeffers Terry, Mary ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; AGITATION; AKATHISIA; ALERTNESS; ANXIETY; APATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED ENERGY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FACIAL EXPRESSION; FEMALE; HUMAN; HYPERSALIVATION; IRRITABILITY; MALE; MOTOR DYSFUNCTION; MUSCLE STIFFNESS; OUTCOMES RESEARCH; OVERNUTRITION; OVERT AGGRESSION SCALE; PACING; PSYCHOSOCIAL WITHDRAWAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCHOOL DROPOUT; SEDATION; SIDE EFFECT; TREMOR; WEIGHT GAIN;

ADOLESCENT; AGGRESSION; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHILD; COMORBIDITY; CONDUCT DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PERSONALITY ASSESSMENT; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 42549085631     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0007     Document Type: Article

References (68)

1. Aman MG, Tasse MJ, Rojahn J, Hammer D: The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Develop Disabil 17:41-57, 1996.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Group RDBS: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
3. American Academy of Child and Adolescent Psychiatry: Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry 36(10 Suppl):122S-139S, 1997.
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Press, 1994.
5. AstraZeneca Pharmaceuticals: Seroquel™ Investigator's Brochure, 7th ed. Wayne (Pennsylvania), 2002.
6. Bambauer KZ, Connor DF: Characteristics of aggression in clinically referred children. CNS Spectr 10:709-718, 2005.
7. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
8. Barzman D, Gernert B, Delbello M: Quetiapine for chronic motor tic disorder. Am J Psychiatry 161:1307, 2004.
9. Borduin CM, Mann BJ, Cone LT, Henggeler SW, Fucci BR, Blaske DM, Williams RA: Multisystemic treatment of serious juvenile offenders: Long-term prevention of criminality and violence. J Consult Clin Psychology 63:569-578, 1995.
10. Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360, 2005.
11. Cohen, J: Statistical Power Analysis for the Behavioral Sciences (2nd ed.). Hillsdale (New Jersey), Lawrence Earlbaum Associates, 1988.
12. Cole P, Rabasseda X: Quetiapine in bipolar disorder: Increasing evidence of efficacy and tolerability. Drugs Today (Barc) 40:837-852, 2004.
13. Conners CK: Manual For Conners' Rating Scales. North Tonawanda, New York, Multi-Health Systems, Inc., 1990.
14. Connor DF: Aggression and Antisocial Behavior in Children and Adolescents: Research and Treatment. New York, Guilford Press, 2002.
15. Connor DF, McLaughlin TJ: Aggression and diagnosis in psychiatrically referred children. Child Psychiatry Hum Dev 37:1-14, 2006.
16. Connor DR, Ozbayrak KR, Benjamin S, Ma Y, Fletcher KE: A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry 36:826-834, 1997.
17. Connor DF, Melloni RH, Jr., Harrison RJ: Overt categorical aggression in referred children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 37:66-73, 1998.
18. Connor DF, Fletcher KE, Wood JS: Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62:967-974, 2001.
19. Connor DF, Boone RT, Steingard RJ, Lopez ID, Melloni RH, Jr.: Psychopharmacology and aggression: II. A meta-analysis of nonstimulant medication effects on overt aggression-related behaviors in youth with SED. J Emotion Behav Disorders 11:157-168, 2003.
20. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72, 2005.
21. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM: A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 45:305-313, 2006.
22. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 29:321-36, 1993.
23. Findling RL: Use of quetiapine in children and adolescents. J Clin Psychiatry 63 (Suppl)13:27-31, 2002.
24. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000a.
25. Findling RL, McNamara NK, Gracious BL: Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 1:935-945, 2000b.
26. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
27. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004a.
28. Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL: Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14:287-294, 2004b.
29. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK: Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 45:792-800, 2006.
30. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK: A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol 17:1-9, 2007.
31. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Clinical drug monitoring in child and adolescent psychiatry: Side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 16:308-316, 2006.
32. Frick PJ: Conduct Disorders and Severe Antisocial Behavior. New York, Plenum Press, 1998.
33. Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, Abikoff H, Chrisman AK, Chuang S, Findling RL, March J, Scahill L, Walkup J, Riddle MA: Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 43:1488-1496, 2004.
34. Guy W: Assessment Manual for Psychopharmacology. Washington (DC), U.S. Department of Health, Education, and Welfare, 1976.
35. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64:2291-2314, 2004.
36. Henggeler SW, Schoenwald SK, Rowland M, Cunningham P: Serious Emotional Disturbance in Children and Adolescents: Multisystemic Therapy. New York, Guilford Press, 2002.
37. Kazdin AE: Conduct Disorders in Childhood and Adolescence. London, Sage, 1995.
38. Kazdin AE: Practitioner review: Psychosocial treatments for conduct disorder in children. J Child Psychol Psychiatry 38:161-178, 1997.
39. Kemph JP, DeBane CL, Levin GM, Jarecke R, Miller RL: Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32:577-581, 1993.
40. Kessler RC, Coccaro EF, Fava M, Jaeger S, Jin R, Walters E: The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 63:669-678, 2006.
41. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R: Prior juvenile diagnoses in adults with mental disorder: Developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry 60:709-717, 2003.
42. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW: Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit/hyperactivity disorder, conduct/oppositional-defiant disorder, and aggression: A prospective, open-label study. J Child Adolesc Psychopharmacol 17:334-347, 2007.
43. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
44. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K: Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial. J Child Adolesc Psychopharmacol 13:75-82, 2003.
45. McCracken JT, McGough JJ, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohen N, Scahill L, Martin AM, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, RUPP Network: Risperidone in children with autism and serious behavioral problems. NEJM 347:314-321, 2002.
46. Munetz MR, Benjamin S: How to examine patients using the abnormal involuntary movement scale. Hosp Com Psychiatry 39:1172-1177, 1988.
47. Orvaschel H: Schedule for Affective Disorders and Schizophrenia for School-Age Children. Epidemiologic version-5. Center for Psychological Studies. Nova Southeastern University, Fort Lauderdale, Florida, 1995.
48. Pae CU, Nassir Ghaemi S, Kim TS, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH: Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: A preliminary trial. Int Clin Psychopharmacol 20:327-330, 2005.
49. Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145-161, 2003.
50. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS: Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. J Can Acad Child Adolesc Psychiatry 15:27-39, 2006.
51. Pathak S, Johns ES, Kowatch RA: Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: A case series. J Child Adolesc Psychopharmacol 15:696-702, 2005.
52. Pierre JM, Wirshing DA, Wirshing WC, Rivard JM, Marks R, Mendenhall J, Sheppard K, Saunders DG: High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res 73:373-375, 2005.
53. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, Macintyre Ii JC, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003.
54. Scott S: Aggressive behaviour in childhood. BMJ: 202-206, 1998.
55. Scott S, Knapp M, Henderson J, Maughan B: Financial cost of social exclusion: Follow up study of antisocial children into adulthood. BMJ 323:191, 2001.
56. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001.
57. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19, 1970.
58. Sjostrom O, Holst D: Validity of a questionnaire survey: Response patterns in different subgroups and the effect of social desirability. Acta Odontol Scand 60:136-140, 2002.
59. Snyder R, Turgay A, Aman MG, Binder C, Fisman S, Carroll A: Effects of risperidone on conduct and disruptive behavior disorders in children and adolescents with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
60. Steiner H: Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry 36:122S-39S, 1997.
61. Steiner H, Cauffman E: Juvenile justice, delinquency, and psychiatry. Child Adolesc Psychiatr Clin N Am 7:653-672, 1998.
62. Steiner H, Saxena K, Chang K: Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectrums 8:298-308, 2003.
63. Tandon R: Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol 19:559-563, 2004.
64. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
65. Valerius G, Biedermann NC, Schaerer LO, Langosch JM: Quetiapine in the treatment of rapid-cycling bipolar II disorder with comorbid anxiety and social phobia - a case report. Pharmacopsychiatry 38:225-226, 2005.
66. Van Bellinghen M, De Troch C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5-13, 2001.
67. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M: Quetiapine monotherapy for mania associated with bipolar disorder: Combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 21:923-934, 2005.
68. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D: The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143:35-39, 1986.